Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ATTO

Attovia Therapeutics Inc

20.38

Aug 06 • 3:59 PM ET -1.52 (-6.94%)

20.38

Aftermarket • 5:16 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Today, 4:11 PMAttovia Therapeutics announces closing of its upsized IPO, raising approximately $332.4 million as underwriters fully exercise their option to purchase additional shares.

Peers: BDRX ELOX SCNI BBLG SLXN VBIO GNPX MBRX AZTR CLDI

Scroll to Statements

Index	-
Market Cap	785.24M
Enterprise Value	915.65M
Income	-
Sales	-
Book/sh	-2.92
Cash/sh	3.44
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 05, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	5.92
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.94
Current Ratio	13.94
Debt/Eq	0.04
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	-
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.60%
SMA50	-3.60%
SMA200	-3.60%
Trades

Shs Outstand	43.03M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	22.79 -10.57%
52W Low	20.21 0.84%
Volatility	- -
ATR (14)	2.50
RSI (14)	-
Beta	-
Rel Volume	0.08
Avg Volume	4.91M
Volume	413,118

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-2.95%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	21.90
Price	20.38
Change	-6.94%

Today 04:05PM	Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.94%
05:57AM	Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq (PR Newswire)

Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing next-generation biotherapeutics for immune-mediated diseases. It delivers treatments through its platform, ATTOBODY. The company was founded by Tao Fu, Zaneta Odrowaz, and Petter Veiby on December 16, 2022 and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Frazier Life Sciences XI, L.P.	10% Owner	Aug 06 '26	Buy	17.00	588,235	9,999,995	6,154,213	Aug 06 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATTO

Attovia Therapeutics Inc

Upgrade your Finviz experience